§ 02 · Comparison

Compare regulatory pathways side-by-side

Benchmark MAHMAH, GMPGMP, HTAHTA and pathway requirements across up to three markets.

Country A

Country B

Country C

Highlight differences

Criterion	🇻🇳Vietnam Fees verified 12 September 2026	🇪🇺European Union Fees verified 12 September 2026
Authority & dossier
Fee confirmation	Fees verified 12 September 2026	Fees verified 12 September 2026
Regulatory authority	DAV	EMA
English submissions	Yes	Yes
CTD accepted	Yes	Yes
eCTD accepted	No	Yes
Reliance pathway	Available	Available
Reference agencies	FDA (US), EMA, MHRA (UK), Health Canada +4	Not stated
Lead pathway (timeline & fees), New Drug Registration, Standard Visa · Centralised Procedure
Pathway name	New Drug Registration, Standard Visa	Centralised Procedure
Approval timeline	270-540 days	210-277 days
Headline fee and pathway	VND 11,000,000, New Drug Registration, Standard Visa	EUR 865,200, Centralised Procedureconditional on other
Recurring charges	No recurring fee	EUR 232,400 a year, per marketing authorisation, other applications
Local representative	Required	Required
Local manufacturing	Not required	Not required
GMP inspection	Required	Required
MAH & local presence
Local entity required	Yes	Yes
Local responsible person	Yes	Yes
RP role	Visa holders must designate a registered pharmacist (Chief Pharmacist) responsible for quality and pharmacovigilance, and a contact for the National DI&ADR Centre.	Qualified Person Responsible for Pharmacovigilance (QPPV), must reside and operate in the EU/EEA, is responsible for the establishment and maintenance of the pharmacovigilance system. A Qualified Person (QP) in the EU/EEA performs batch certification under Article 51 of Directive 2001/83/EC. Local Contact Person for pharmacovigilance required in each Member State where the product is marketed (since 2012 GVP).
Accelerated pathways
Designations available	2 designations	6 designations
Examples	Public Health Emergency / Conditional Visa, Auto-extension of Marketing Authorisation	Accelerated Assessment, Conditional Marketing Authorisation, Authorisation under Exceptional Circumstances +3
Post-approval lifecycle
Variations framework	Variations classified per Circular 08/2022/TT-BYT and Circular 12/2025/TT-BYT into Major Variation (DAV approval), Minor Variation (notification or prior approval) and Administrative Variation, broadly aligned with ASEAN Variation Guideline.	Commission Regulation (EC) 1234/2008 establishes four categories: Type IA (minor, Do and Tell, 12-month notification), Type IAIN (minor, immediate notification), Type IB (minor, Tell, Wait, and Do, 30-day default), Type II (major, prior approval, 60 to 90 days), and Extensions (Annex I changes, full review). Worksharing procedures consolidate variations across multiple authorisations.
Renewal cycle	Visa is valid for 5 years (or 3 years for products with conditional approval / new active substances), renewable; Circular 08/2022 introduced auto-extension during DAV review of renewals.	Initial 5-year renewal, application 9 months before expiry. After the first renewal, MA is granted for unlimited duration unless the CHMP/NCA, on justified grounds relating to pharmacovigilance, decides on one additional 5-year renewal.
Pharmacovigilance	Vietnam's National Centre of Drug Information and Adverse Drug Reactions Monitoring (DI&ADR Centre) coordinates national ADR reporting (Vietnam is a member of the WHO Programme for International Drug Monitoring, Uppsala). Visa holders must submit PSURs aligned to ICH E2C(R2), report serious ADRs within statutory timelines, and maintain a Risk Management Plan (RMP) for new active substances.	Comprehensive PV framework under Directive 2010/84/EU and Regulation (EU) 1235/2010, codified in Good Pharmacovigilance Practices (GVP). Pharmacovigilance System Master File (PSMF) required. Periodic Safety Update Reports (PSURs) on EU-harmonised birth-date list. Risk Management Plans for all new MAs and significant variations. Suspected serious ADR reporting to EudraVigilance within 15 days. Black triangle (▼) for additional monitoring of selected products.
Unlicensed access
Named Patient Supply	Available	Available
Compassionate Use	Available	Available
Emergency Import	Available	Available
Parallel Import	Not permitted	Permitted
Clinical trials
CTA approval	Required	Required
Ethics approval	Yes	Yes
CTA timeline	60-120 days	60-106 days
GCP standard	ICH E6(R2) GCP; MoH Vietnamese GCP guidelines	ICH E6(R3), Commission Regulation (EU) 2024/2748 transposing R3, applicable from 23 July 2025
Pricing & reimbursement
Price regulation	Regulated	Regulated
Reference pricing	Yes	Yes
HTA required	No	Yes
HTA body	MoH Reimbursement Drug List Council (HTA capability developing, Health Strategy and Policy Institute, HSPI)	EU HTA Coordination Group (EUnetHTA legacy); national HTA bodies (NICE, HAS, G-BA/IQWiG, AIFA, AEMPS, etc.)

Verdict colours indicate lower, moderate, or higher regulatory burden, they're not value judgements on a market.

Authority & dossier

Fee confirmation

VietnamFees verified 12 September 2026
European UnionFees verified 12 September 2026

Regulatory authority

VietnamDAV
European UnionEMA

English submissions

VietnamYes
European UnionYes

CTD accepted

VietnamYes
European UnionYes

eCTD accepted

VietnamNo
European UnionYes

Reliance pathway

VietnamAvailable
European UnionAvailable

Reference agencies

VietnamFDA (US), EMA, MHRA (UK), Health Canada +4
European UnionNot stated

Lead pathway (timeline & fees), New Drug Registration, Standard Visa · Centralised Procedure

Pathway name

VietnamNew Drug Registration, Standard Visa
European UnionCentralised Procedure

Approval timeline

Vietnam270-540 days
European Union210-277 days

Headline fee and pathway

VietnamVND 11,000,000, New Drug Registration, Standard Visa
European UnionEUR 865,200, Centralised Procedureconditional on other

Recurring charges

VietnamNo recurring fee
European UnionEUR 232,400 a year, per marketing authorisation, other applications

Local representative

VietnamRequired
European UnionRequired

Local manufacturing

VietnamNot required
European UnionNot required

GMP inspection

VietnamRequired
European UnionRequired

MAH & local presence

Local entity required

VietnamYes
European UnionYes

Local responsible person

VietnamYes
European UnionYes

RP role

VietnamVisa holders must designate a registered pharmacist (Chief Pharmacist) responsible for quality and pharmacovigilance, and a contact for the National DI&ADR Centre.
European UnionQualified Person Responsible for Pharmacovigilance (QPPV), must reside and operate in the EU/EEA, is responsible for the establishment and maintenance of the pharmacovigilance system. A Qualified Person (QP) in the EU/EEA performs batch certification under Article 51 of Directive 2001/83/EC. Local Contact Person for pharmacovigilance required in each Member State where the product is marketed (since 2012 GVP).

Accelerated pathways

Designations available

Vietnam2 designations
European Union6 designations

Examples

VietnamPublic Health Emergency / Conditional Visa, Auto-extension of Marketing Authorisation
European UnionAccelerated Assessment, Conditional Marketing Authorisation, Authorisation under Exceptional Circumstances +3

Post-approval lifecycle

Variations framework

VietnamVariations classified per Circular 08/2022/TT-BYT and Circular 12/2025/TT-BYT into Major Variation (DAV approval), Minor Variation (notification or prior approval) and Administrative Variation, broadly aligned with ASEAN Variation Guideline.
European UnionCommission Regulation (EC) 1234/2008 establishes four categories: Type IA (minor, Do and Tell, 12-month notification), Type IAIN (minor, immediate notification), Type IB (minor, Tell, Wait, and Do, 30-day default), Type II (major, prior approval, 60 to 90 days), and Extensions (Annex I changes, full review). Worksharing procedures consolidate variations across multiple authorisations.

Renewal cycle

VietnamVisa is valid for 5 years (or 3 years for products with conditional approval / new active substances), renewable; Circular 08/2022 introduced auto-extension during DAV review of renewals.
European UnionInitial 5-year renewal, application 9 months before expiry. After the first renewal, MA is granted for unlimited duration unless the CHMP/NCA, on justified grounds relating to pharmacovigilance, decides on one additional 5-year renewal.

Pharmacovigilance

VietnamVietnam's National Centre of Drug Information and Adverse Drug Reactions Monitoring (DI&ADR Centre) coordinates national ADR reporting (Vietnam is a member of the WHO Programme for International Drug Monitoring, Uppsala). Visa holders must submit PSURs aligned to ICH E2C(R2), report serious ADRs within statutory timelines, and maintain a Risk Management Plan (RMP) for new active substances.
European UnionComprehensive PV framework under Directive 2010/84/EU and Regulation (EU) 1235/2010, codified in Good Pharmacovigilance Practices (GVP). Pharmacovigilance System Master File (PSMF) required. Periodic Safety Update Reports (PSURs) on EU-harmonised birth-date list. Risk Management Plans for all new MAs and significant variations. Suspected serious ADR reporting to EudraVigilance within 15 days. Black triangle (▼) for additional monitoring of selected products.

Unlicensed access

Named Patient Supply

VietnamAvailable
European UnionAvailable

Compassionate Use

VietnamAvailable
European UnionAvailable

Emergency Import

VietnamAvailable
European UnionAvailable

Parallel Import

VietnamNot permitted
European UnionPermitted

Clinical trials

CTA approval

VietnamRequired
European UnionRequired

Ethics approval

VietnamYes
European UnionYes

CTA timeline

Vietnam60-120 days
European Union60-106 days

GCP standard

VietnamICH E6(R2) GCP; MoH Vietnamese GCP guidelines
European UnionICH E6(R3), Commission Regulation (EU) 2024/2748 transposing R3, applicable from 23 July 2025

Pricing & reimbursement

Price regulation

VietnamRegulated
European UnionRegulated

Reference pricing

VietnamYes
European UnionYes

HTA required

VietnamNo
European UnionYes

HTA body

VietnamMoH Reimbursement Drug List Council (HTA capability developing, Health Strategy and Policy Institute, HSPI)
European UnionEU HTA Coordination Group (EUnetHTA legacy); national HTA bodies (NICE, HAS, G-BA/IQWiG, AIFA, AEMPS, etc.)